Clinical Characteristics and Treatment of Langerhans Cell Histiocytosis
- PMID: 26461147
- DOI: 10.1016/j.hoc.2015.06.005
Clinical Characteristics and Treatment of Langerhans Cell Histiocytosis
Abstract
Langerhans cell histiocytosis (LCH) is a disease caused by clonal proliferation of CD1a+/CD207+ cells that is characterized by a spectrum of varying degrees of organ involvement and dysfunction. Treatment of LCH is risk adapted; patients with single lesions may respond well to local treatment, whereas patients with multi-system disease and risk-organ involvement require more intensive therapy. Although survival for patients without organ dysfunction is excellent, mortality rates for patients with organ dysfunction may reach 30% to 40%. For patients with low-risk disease, although cure is almost universal, disease reactivation rates are in excess of 30%.
Keywords: BRAF; Chemotherapy; Langerhans cell histiocytosis; Neurodegeneration; Oncogenes.
Copyright © 2015 Elsevier Inc. All rights reserved.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
